Nanoparticle-mediated delivery of Neurotoxin-II to the brain with intranasal administration: an effective strategy to improve antinociceptive activity of Neurotoxin

References

• DiNunzio JC, Williams RO 3rd. (2008). CNS disorders–current treatment options and the prospects for advanced therapies. Drug Dev Ind Pharm, 34:1141–1167.
   PubMed Web of Science ®Google Scholar
• Lambert DM. (2000). Rationale and applications of lipids as prodrug carriers. Eur J Pharm Sci, 11 Suppl 2:S15–S27.
   PubMed Web of Science ®Google Scholar
• Bodor N, Buchwald P. (1999). Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv Drug Deliv Rev, 36(2–3):229–254.
   PubMed Web of Science ®Google Scholar
• Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. (2007). Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev, 59:454–477.
   PubMed Web of Science ®Google Scholar
• Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA. (2008). Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv, 5:155–174.
   PubMed Web of Science ®Google Scholar
• Lockman PR, Mumper RJ, Khan MA, Allen DD. (2002). Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm, 28:1–13.
   PubMed Web of Science ®Google Scholar
• Jiang L, Gao L, Wang X, Tang L, Ma J. (2010). The application of mucoadhesive polymers in nasal drug delivery. Drug Dev Ind Pharm, 36:323–336.
   PubMed Web of Science ®Google Scholar
• Illum L. (2000). Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci, 11:1–18.
   PubMed Web of Science ®Google Scholar
• Illum L. (2004). Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol, 56:3–17.
   PubMed Web of Science ®Google Scholar
• Cura JE, Blanzaco DP, Brisson C, Cura MA, Cabrol R, Larrateguy L et al. (2002). Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer. Clin Cancer Res, 8:1033–1041.
   PubMed Web of Science ®Google Scholar
• Zhang HL, Han R, Chen ZX, Chen BW, Gu ZL, Reid PF, et al. (2006). Opiate and acetylcholine-independent analgesic actions of crotoxin isolated from crotalus durissus terrificus venom. Toxicon, 48:175–182.
   PubMed Web of Science ®Google Scholar
• Tsetlin V. (1999). Snake venom alpha-neurotoxins and other ‘three-finger’ proteins. Eur J Biochem, 264:281–286.
   PubMedGoogle Scholar
• Lu QM, Meng QX, Li DS, Zhu SW, Jia WH, Xiong YL, et al. (2002). Comparative study of three short-chain neurotoxins from the venom of Naja kaouthia (Yunnan, China). J Nat Toxins, 11: 221–229.
   PubMedGoogle Scholar
• Tu AT. (1973). Neurotoxins of animal venoms: snakes. Annu Rev Biochem, 42:235–258.
   PubMed Web of Science ®Google Scholar
• Yang CC. (1974). Chemistry and evolution of toxins in snake venoms. Toxicon, 12:1–43.
   PubMed Web of Science ®Google Scholar
• Rang HP. (1974). Acetylcholine receptors. Q Rev Biophys, 7:283–399.
   PubMed Web of Science ®Google Scholar
• Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C et al. (2002). Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target, 10:317–325.
   PubMed Web of Science ®Google Scholar
• Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS et al. (2004). Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer, 109:759–767.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Feng J, Chen J, Zhu X, Li F. (2008). Brain transport of Neurotoxin-I with PLA nanoparticles through Intranasal Administration in Rats: A Microdialysis Study. Biopharm Drug Dispos, 29:431–439.
   PubMed Web of Science ®Google Scholar
• Huang G, Zhang N, Bi X, Dou M. (2008). Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity. Int J Pharm, 355:314–320.
   PubMed Web of Science ®Google Scholar
• Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. (2008). Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer’s disease. Brain Res, 1200:159–168.
   PubMed Web of Science ®Google Scholar
• Löbenberg R, Araujo L, von Briesen H, Rodgers E, Kreuter J. (1998). Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J Control Release, 50:21–30.
   PubMed Web of Science ®Google Scholar
• Fasmer OB, Berge OG, Hole K. (1985). Changes in nociception after lesions of descending serotonergic pathways induced with 5,6-dihydroxytryptamine. Different effects in the formalin and tail-flick tests. Neuropharmacology, 24:729–734.
   PubMed Web of Science ®Google Scholar
• Hunskaar S, Hole K. (1987). The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain, 30:103–114.
   PubMed Web of Science ®Google Scholar
• Yan Z, Wang YP, Jiao CJ, Li FM, Liang YM, Li ZX. (2005) High-performance liquid chromatographic analysis of neurotoxin β-N-oxalyl-α, β-diaminopropionic acid (β-ODAP), its non-neurotoxic isomer α-ODAP and other free amino acids in Lathyrus sativus. Chromatographia, 61(5–6): 231–236.
   Web of Science ®Google Scholar
• Kreuter J. (2001). Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev, 47:65–81.
   PubMed Web of Science ®Google Scholar
• Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R. (2002). Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target, 10:317–325.
   PubMed Web of Science ®Google Scholar
• Dyer AM, Hinchcliffe M, Watts P, Castile J, Jabbal-Gill I, Nankervis R et al. (2002). Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm Res, 19:998–1008.
   PubMed Web of Science ®Google Scholar
• Cui Z, Mumper RJ. (2002). Intranasal administration of plasmid DNA-coated nanoparticles results in enhanced immune responses. J Pharm Pharmacol, 54:1195–1203.
   PubMed Web of Science ®Google Scholar
• Lemarchand C, Gref R, Couvreur P. (2004). Polysaccharide-decorated nanoparticles. Eur J Pharm Biopharm, 58:327–341.
   PubMed Web of Science ®Google Scholar
• Croy JE, Brandon T, Komives EA. (2004). Two apolipoprotein E mimetic peptides, ApoE(130-149) and ApoE(141-155)2, bind to LRP1. Biochemistry, 43:7328–7335.
   PubMed Web of Science ®Google Scholar
• Dergunov AD. (2004). Apolipoprotein E structure and substrate and receptor-binding activities of triglyceride-rich human plasma lipoproteins in normo- and hypertriglyceridemia. Biochemistry Mosc, 69:720–737.
   PubMed Web of Science ®Google Scholar
• Kreuter J. (2004). Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J Nanosci Nanotechnol, 4:484–488.
   PubMed Web of Science ®Google Scholar
• Hosseinzadeh H, Ramezani M, Salmani G. (2000). Antinociceptive, anti-inflammatory and acute toxicity effects of Zataria multiflora Boiss extracts in mice and rats. J Ethnopharmacol, 73:379–385.
   PubMed Web of Science ®Google Scholar